Parliamentary Written Questions

Entries are in reverse chronological order 

To ask the Secretary of State for Health, what assessment he has made of the costs and benefits to the NHS of widening access to the HPV vaccine known as Gardasil.
Jonathan Lord, Conservative, Woking, (HC, 20 April 2017, Ref: 71469)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-04-20/71469/

To ask the Secretary of State for Health, how many reports of (a) all adverse and (b) serious adverse reactions to (i) Cervarix, (ii) Gardasil and (iii) generic human papilloma virus vaccines the Medicines and Healthcare Products Regulatory Agency has received to date.
Stuart McDonald, Shadow SNP Spokesperson (Immigration, Asylum and Border Control)
(HC, 13 April 2017, Ref: 70973)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-04-13/70973/

To ask Her Majesty’s Government what funding they provide, and to which countries, for the detection and treatment of breast and gynaecological cancer
Baroness Tonge Independent Liberal Democrat (HL, 20 March 2017, Ref: HL6183)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2017-03-20/HL6183/

To ask Her Majesty’s Government what priority they give to HPV vaccination in developing country programmes
Baroness Tonge Independent Liberal Democrat (HL, 20 March 2017, Ref: HL6184)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2017-03-20/HL6184/

To ask Her Majesty’s Government whether they will consider developing a campaign to vaccinate all girls in developing countries against HPV
Baroness Tonge Independent Liberal Democrat (HL, 20 March 2017, Ref: HL6185)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2017-03-20/HL6185/

To ask the Secretary of State for Health, what the level of cervical screening uptake is in Wolverhampton Clinical Commissioning Group; what steps his Department is taking to increase cervical screening uptake among women in Wolverhampton; and if he will make a statement.
Emma Reynolds, Labour, Wolverhampton North East, (HC, 9 February 2017, Ref: 63890)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-02-09/63890/

To ask the Secretary of State for Health, pursuant to the Answer of 16 September 2016 to Question 45640, how many participants have received the HPV vaccine as part of the pilot to provide that vaccine to gay and bisexual men.
Sharon Hodgson, Shadow Minister (Public Health), (HC, 31 January 2017, Ref: 62520)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-01-31/62520/

To ask the Secretary of State for Health, what steps his Department is taking with NHS England to ensure that gay and bisexual men sign up to the HPV vaccination pilot.
Sharon Hodgson, Shadow Minister (Public Health), (HC, 31 January 2017 2017, Ref: 62579)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-01-31/62579/

To ask the Secretary of State for Health, what steps his Department is taking to make cervical screening available in additional (a) GP surgeries and (b) local healthcare settings.
John Baron Chair, Foreign Affairs Sub-Committee, (HC, 26 January 2017, Ref: 61854)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-01-26/61854/

To ask the Secretary of State for Health, whether cervical screening is available to all women at contraception and sexual health clinics.
John Baron Chair, Foreign Affairs Sub-Committee, (HC, 25 January 2017, Ref: 61533)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-01-25/61533/

To ask the Secretary of State for Health, if he will make cervical screening available to women at every contraception and sexual health clinic; and if he will make a statement.
David Amess, Conservative, Southend West, (HC, 25 January 2017, Ref: 61552)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-01-25/61552/

To ask the Secretary of State for Health, what steps his Department is taking to increase cervical screening uptake among women in (a) Newcastle, (b) the North-East and (c) England; and if he will make a statement.
Catherine McKinnell, Labour, Newcastle upon Tyne North, (HC, 24 January 2017, Ref: 61387)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2017-01-24/61387/

To ask the Secretary of State for Health, what steps his Department is taking to ensure the safety of the HPV vaccination.
Graham Brady Chair, Conservative Party 1922 Committee, (HC, 1 November 2016, Ref: 51320)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-11-01/51320/

To ask the Secretary of State for Health, how many complaints his Department received in relation to vaccination against human papilloma virus in each month of 2016.
John Mann Labour, Bassetlaw, (HC, 7 October 2016, Ref: 47258)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-10-07/47258/

To ask the Secretary of State for Health, on what date HPV vaccinations were made available to men who have sex with men; and how many such men have received that vaccination since that date.
Mike Freer Conservative, Finchley and Golders Green, (HC, 8 September 2016, Ref: 45640)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-09-08/45640/

To ask the Secretary of State for Health, what guidance he has issued to schools on systems for (a) warning about and (b) responding to serious reactions to HPV vaccines.
John Mann Labour, Bassetlaw, (HC, 2 September 2016, Ref: 44213)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-09-02/44213/

To ask the Secretary of State for Health, what the take-up rate is of the HPV vaccine for girls in (a) Ashfield constituency, (b) Nottinghamshire and (c) the UK.
Gloria De Piero Labour, Ashfield, (HC, 20 June 2016, Ref: 41090)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-06-20/41090/

To ask the Secretary of State for Health, how many people under the age of 18 have died after receiving the HPV vaccination in the last three years.
Jim Shannon, Shadow DUP Spokesperson (Health), Shadow DUP Spokesperson (Transport), Shadow DUP Spokesperson (Equality), (HC, 8 June 2016, Ref: 39887)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-06-08/39887/

To ask the Secretary of State for Health, whether the Parliamentary Under Secretary of State for Public Health has seen the complaint by the Nordic Cochrane Centre to the European Medicines Agency regarding maladministration at that organisation; and if he will make a statement.
Andrew Gwynne, Shadow Minister (Health), (HC, 26 May 2016, Ref: 98834)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-05-26/38834/

To ask the Secretary of State for Health, what the cost has been of delivering the HPV vaccination programme to girls excluding the cost of procuring the vaccine itself in each of the three most recent years for which data is available.
John Baron Chair, Foreign Affairs Sub-Committee, (HC, 24 May 2016, Ref: 38179)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-05-24/38179/

To ask the Secretary of State for Health, whether he plans for the HPV vaccination programme at sexual health clinics for men who have sex with men to be rolled out nationally at the earliest opportunity or to be implemented through initial pilot projects.
Andrew Gwynne, Shadow Minister (Health), (HC, 24 May 2016, Ref: 38132)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-05-24/38132/

To ask the Secretary of State for Health, what the timetable is for implementing HPV vaccinations at sexual health clinics for men who have sex with men.
Andrew Gwynne, Shadow Minister (Health), (HC, 24 May 2016, Ref: 38133)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-05-24/38133/

To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether the time period referred to when providing details of the not anticipated reduction in genital warts associated with the bivalent vaccine takes into account the impact of the introduction of the quadrivalent vaccine in 2012.
Ben Bradshaw, Labour, Exeter, (HC, 19 March 2016, Ref: 34694)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-04-19/34694/

To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether there has been any lasting duration of the HPV reduction that Public Health England have associated with the bivalent vaccine.
Ben Bradshaw, Labour, Exeter, (HC, 19 March 2016, Ref: 34695)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-04-19/34695/

To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department’s policies of the 2016 paper by Mesher and others, Reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.
Ben Bradshaw, Labour, Exeter, (HC, 19 March 2016, Ref: 34696)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-04-19/34696/

To ask the Secretary of State for Health, what estimate he has made of the potential change in the prevalence of genital warts following the award of the contract for supply of human papillomavirus vaccine to the bivalent vaccine.
Ben Bradshaw, Labour, Exeter, (HC, 17 March 2016, Ref: 31529)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-17/31529/

To ask the Secretary of State for Health, what estimate his Department has made of the numbers of children born with recurrent respiratory papillomatosis from mothers who have not been protected from genital warts through the HPV vaccination programme in each year since that programme began; and what assessment he has made of the implications for his policy of trends in those numbers.
Paula Sherriff, Labour, Dewsbury, (HC, 15 March 2016, Ref: 31084)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31084/

To ask the Secretary of State for Health, whether the current multi-purpose vaccine will continue to be used following the recent tender for supply of that vaccine to the UK HP vaccination programme.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31112)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31112/

To ask the Secretary of State for Health, what the decision making criteria is for the award of the contract for the supply of human papilloma virus vaccine.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31114)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31114/

To ask the Secretary of State for Health, what weighting is being provided to the prevention of genital warts in the decision making process for the contract for the supply of human papilloma virus vaccine.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31115)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31115/

To ask the Secretary of State for Health, if his Department will provide an evaluation of the clinical differences between the quadrivalent and bivalent vaccines available for use in the HPV vaccination programme.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31116)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31116/

To ask the Secretary of State for Health, what assessment his Department has made of the effect of the quadrivalent vaccine used in the HPV vaccination programme on genital wart incidence.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31117)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31117/

To ask the Secretary of State for Health, if he has assessed whether the bivalent vaccine previously used for the HPV vaccination programme had an effect on the incidence of genital warts in the UK.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31118)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31118/

To ask the Secretary of State for Health, what assessment his Department has made on the likely incidence of recurrent respiratory papillomatosis in the event that the (a) quadrivalent vaccine is maintained for UK HPV vaccination programme for girls and (b) bivalent vaccine is introduced for the UK HPV vaccination programme for girls.
Ben Bradshaw, Labour, Exeter, (HC, 15 March 2016, Ref: 31120)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-15/31120/

To ask the Secretary of State for Health, what international comparisons his Department is drawing on to inform implementation of a gender-neutral HPV vaccination programme.
Paula Sherriff, Labour, Dewsbury, (HC, 14 March 2016, Ref: 30899)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-03-14/30899/

To ask Her Majesty’s Government what estimates they have made of the likely benefits of providing the quadrivalent HPV vaccine to all adolescents in the UK on a gender-neutral basis.
Lord Storey, Liberal Democrat Lords Spokesperson (Education), (HL, 8 March 2017, Ref: HL6798
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2016-03-08/HL6798/

To ask Her Majesty’s Government whether there are any other circumstances in which 2,500/100,000 serious adverse events and 3,300/100,000 cases of autoimmune disorders, as reported by the human papilloma virus vaccine manufacturers, would be accepted in order to try to prevent the occurrence of 10/100,000 cases of cervical cancer.
The Countess of Mar, Deputy Chairman of Committees, Deputy Speaker (Lords), (HL, 8 March 2016, Ref: HL6834)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2016-03-08/HL6834/

To ask Her Majesty’s Government when a vaccine will be procured for the human papilloma virus vaccination programme for men who have sex with men.
Lord Black of Brentwood, Conservative, (HL, 9 February 2016, Ref: HL6027)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2016-02-09/HL6027/

To ask Her Majesty’s Government whether the procurement of a human papilloma virus vaccination programme currently taking place includes the vaccine needed for men who have sex with men.
Lord Black of Brentwood, Conservative, (HL, 9 February 2016, Ref: HL6028)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2016-02-09/HL6028/

To ask Her Majesty’s Government when the human papilloma virus vaccination programme for men who have sex with men will commence.
Lord Black of Brentwood, Conservative, (HL, 9 February 2016, Ref: HL6029)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2016-02-09/HL6029/

To ask the Secretary of State for Health, what estimate his Department has made of how many men who have sex with men (MSM) are expected to receive the HPV vaccine each year as a result of the Joint Committee on Vaccination and Immunisation’s recommendation that it be offered at sexual health clinics; and what proportion of the MSM population aged up to 45 his Department estimates will have been vaccinated within (a) one year, (b) five years and (c) 10 years of that vaccine first being so offered.
Sarah Wollaston, Chair, Health Committee, (HC, 4 February 2016, Ref: 25883)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-02-04/25883/

To ask Her Majesty’s Government whether the planned future HPV vaccine programme will also cover elimination of genital warts.
Baroness Gould of Potternewton, Deputy Speaker (Lords), (HL, 4 February 2016, Ref:HL5925)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2016-02-04/HL5925/

To ask the Secretary of State for Health, whether he has received requests to expedite the timetable of the Joint Committee on Vaccination and Immunisation for a decision on HPV vaccination for boys; and whether he plans to review that timetable.
Sarah Wollaston, Chair, Health Committee, (HC, 2 February 2016, Ref: 25359)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-02-02/25359/

To ask the Secretary of State for Health, with reference to the Answer of 28 January 2016 to Question 23467, what progress has been made on the procurement of the HPV vaccine.
Danny Kinahan, UUP, South Antrim, (HC, 1 February 2016, Ref: 25038)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-02-01/25038/

To ask the Secretary of State for Health, what progress his Department is making on rolling out HPV vaccinations to men who have sex with men.
Mike Freer, Conservative, Finchley and Golders Green, (HC, 3 February 2016, Ref: 903556)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-02-03/903556/

To ask the Secretary of State for Health, whether his Department plans to extend the age group entitled to receive the human papilloma virus vaccinations for women.
Maria Caulfield, Conservative, Lewes, (HC, 22 January 2016, Ref: 23801)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-01-22/23801/

To ask the Secretary of State for Health, whether his Department plans to carry out an equality impact assessment of the tender decision on the universal girls vaccination programme for the human papilloma virus; and what the implications are for that programme of a decision to award it to one using the bivalent vaccine.
Maria Caulfield, Conservative, Lewes, (HC, 22 January 2016, Ref: 23802)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-01-22/23802/

To ask the Secretary of State for Health, what steps his Department plans to take to ensure that the men who have sex with men population is aware of the availability of the HPV vaccination at sexual health clinics.
Danny Kinahan, UUP, South Antrim, (HC, 20 January  2016, Ref: 23466)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-01-20/23466/

To ask the Secretary of State for Health, when HPV vaccinations are planned to be available at sexual health clinics to men who have sex with men?
Danny Kinahan, UUP, South Antrim, (HC, 20 January 2016, Ref: 23467)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2016-01-20/23467/

To ask the Secretary of State for Health, what estimate he has made of the (a) reduction in cases of and deaths from human pappillomavirus (HPV) as a result of the introduction of the HPV vaccine to the UK schedule in 2008, (b) number of HPV vaccinations administered in each year since that programme began and (c) cost of delivering that programme in each year since 2008.
Andrew Gwynne, Shadow Minister (Health), (HC, 24 November 2015, Ref: 17428)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-11-24/17428/

To ask the Secretary of State for Health, what steps he is taking to promote awareness in schools of the HPV vaccine.
Jim Shannon, Shadow DUP Spokesperson (Health), Shadow DUP Spokesperson (Transport), Shadow DUP Spokesperson (Equality), (HC, 9 November 2015, Ref: 15495)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-11-09/15495/

To ask the Secretary of State for Health, what assessment his Department has made of the implications for its policy of the potential link between the HPV Vaccine and Postural Orthostatic Tachycardia Syndrome; and what assessment he has made of the effect of such a link on the progress of the Government’s HPV vaccination programme.
Andrew Rosindell, Conservative, Romford, (HC, 13 October 2015, Ref: 11694)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-10-13/11694/

To ask the Secretary of State for Health, whether the Joint Committee on Vaccination and Immunisation will conduct an equality impact assessment as part of its consideration of whether all adolescent boys should be included in the national HPV vaccination programme in order to meet its obligations under the general equality duty of the Equality Act 2010.
John Baron, Conservative, Basildon and Billericay, (HC, 15 July 2015, Ref: 7298)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-07-15/7298/

To ask Her Majesty’s Government why only 16.8 per cent of reports of serious adverse events relating to human papilloma virus (HPV) vaccines under the Yellow Card Scheme have been followed up, according to the response by the Medicines and Healthcare products Regulatory Agency to a freedom of information request on 25 June; how this compares to the percentage of yellow-card reports followed up for all vaccines; and whether they now plan to follow up all reported serious adverse events relating to HPV vaccines in order to ascertain recovery rates.
The Countess of Mar, Deputy Chairman of Committees, Deputy Speaker (Lords), (HL, 7 July 2015, Ref:  HL1164)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2015-07-07/HL1164/

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 16 June (HL229), which indicated that 2,589 serious suspected adverse drug reactions to human papilloma virus vaccines had been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) as at 3 June, and the response by the MHRA to a freedom of information request on 25 June that 2,617 such reactions had been reported as at 24 June, what assessment they have made of the increase in reports over the course of one month.
The Countess of Mar, Deputy Chairman of Committees, Deputy Speaker (Lords), (HL, 7 July 2015, Ref:  HL1165)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2015-07-07/HL1165/

To ask the Secretary of State for Health, if he will make an assessment of the implications for his Department’s policies of the steps taken by the Danish government to examine people suspected of having a negative reaction to HPV vaccines.
Richard Burden, Shadow Minister (Transport), (HC, 6 July 2015, Ref: 5682)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-07-06/5682/

To ask Her Majesty’s Government, to date, how many adverse reactions to (1) Cervarix, (2) Gardasil and (3) generic human papilloma virus vaccines have been reported to the Medicines and Healthcare products Regulatory Agency; for each category, how many of those reports are of serious adverse reactions; and what age-specific rate those figures represent.
The Countess of Mar, Deputy Chairman of Committees, Deputy Speaker (Lords), (HL, 2 June 2015, Ref:  HL229)
http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2015-06-02/HL229/

Pin It on Pinterest

Share This